Markets

Cancer biotech Erytech Pharma sets terms for $100 million US IPO

Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, announced terms for its US IPO on Monday. The company's shares are currently listed on the Euronext Paris under they symbol ERYP.

The Lyon, France-based company plans to raise $100 million by offering 4.26 million ADSs at a price range of $23 to $24. It expects to raise an additional $25 million in a concurrent private placement. At the midpoint of the proposed range, Erytech Pharma would command a fully diluted market value of $415 million.

Erytech Pharma was founded in 2004 and plans to list on the Nasdaq under the symbol ERYP. Jefferies, Cowen & Company and Oddo BHF are the joint bookrunners on the deal. It is expected to price during the week of November 6, 2017.

The article Cancer biotech Erytech Pharma sets terms for $100 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs